ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Binding and crosslinking experiments demonstrate that this protein is the receptor for a recently described interleukin 7 (IL-7)-like factor, thymic stromal lymphopoietin (TSLP). Binding of TSLP ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

“华兴资本医疗与生命科技行业周报”定期发布，专注从资本角度解读一周数据，并提供最新行业观察。医疗与生命科技是华兴资本多年来关注并深耕的领域，目前已为近200个融资及并购项目担任财务顾问。医疗与生命科技行业创新不断涌现，已经发展成为最活跃的行业之一；华 ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...

据“时代财经”报道，3月13日，信达生物前总裁刘刘勇军以小路生物创始人现身易贸医疗举办的BIO CHINA会议现场。会上刘勇军还透露， 他还在给字节跳动当顾问，“字节跳动也在做药”。

Upstream is developing verekitug, the only monoclonal antibody currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, in multiple severe ...

If approved, TSLP inhibitor tezepelumab could reach the market with a broader label than currently-used asthma antibodies, which are approved to treat patient with severe asthma characterised by ...